Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 26, 2026
Trading resumes after Friday halt; ADS ratio change announced October 8 due on or about October 26
$BDRXBiotechnologyDated evidenceClinical and funding risk
BDRX Stock Hub: Biodexa Pharmaceuticals News, Serenta and Cancer Data
A fully enrolled bladder-cancer study approaches its expected readout while Serenta recruitment advances. Funding terms and potential warrant issuance shape what remains for each ADS.
Full research report · PDF
Biodexa Pharmaceuticals ($BDRX), research as of October 26, 2026
12 pages covering The archived research examines Serenta’s event-driven FAP study, the fully enrolled bladder-cancer trial and the limits of earlier efficacy observations. It separates sterling cash and operating consumption from dollar financing proceeds, and explains warrant terms, resale registration and the announced ADS-ratio change. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next company-guided clinical window
Q4 2026
Results from the fully enrolled 166-patient bladder-cancer study are targeted for Q4 2026.
Serenta futility analysis was estimated for early 2027 and database lock around end 2027; both depend on events.
BDRX stock at a glance
Close · October 30, 2026
$3.43
Regular-session close; -12.05% versus $3.9 on October 29, 2026.
Reported cash · June 30, 2026
£3.230M
Sterling balance before subsequent financing; not converted into USD.
Monthly historical operating use
£0.7685M
H1 2026 average, calculated; not a forecast.
September gross financing
~US$2.3M
Completed September 15, 2026; before fees and expenses.
Bladder-cancer study
166 patients
Fully enrolled; Q4 2026 results targeted in September 11 update.
Serenta recruitment
100/168
October 13, 2026 announced actual versus planned enrollment; no efficacy result.
ADS ratio change
1:400
October 8 announcement:400 ordinary shares per ADS, expected about October 26; old 50-share ADS figures are historical.
Serenta futility window
Early 2027
Company estimate based on event accrual, not a fixed date.
Where Biodexa Pharmaceuticals stands now
The constructive scenario would strengthen if eRapa produces useful bladder-cancer results in the fourth-quarter 2026 window and Biodexa obtains enough capital on workable terms to maintain its development plan. The September 11, 2026 update reports the bladder study fully enrolled with 166 patients and the separate Serenta FAP study at 92 of 168 planned participants. The September 24 prospectus confirms a completed September warrant transaction raising approximately US$2.3 million gross. Clinical progress and financing are real developments, but neither yet establishes an approved medicine or a sustainably funded company. Source Source
Clinical progress remains funding dependent. Historical financials are in sterling while ADS prices and named financing proceeds are in USD. The October ADS-ratio change makes pre-change price/share-unit comparisons unsafe without adjustment. Financing and dilution remain material.
The constructive case
The constructive scenario would strengthen if eRapa produces useful bladder-cancer results in the fourth-quarter 2026 window and Biodexa obtains enough capital on workable terms to maintain its development plan. The September 11, 2026 update reports the bladder study fully enrolled with 166 patients and the separate Serenta FAP study at 92 of 168 planned participants. The September 24 prospectus confirms a completed September warrant transaction raising approximately US$2.3 million gross. Clinical progress and financing are real developments, but neither yet establishes an approved medicine or a sustainably funded company. Source Source
The cautious case
The adverse scenario would develop if the bladder-cancer result is disappointing, Serenta encounters execution problems, or capital cannot be raised before resources become inadequate. The June 2026 accounts explicitly identify a material uncertainty relating to going concern. The September financing reduces immediate pressure, but does not establish that all future development is covered. Source Source
Latest Biodexa Pharmaceuticals news
Oct 26, 2026
Trading resumes after Friday halt; ADS ratio change announced October 8 due on or about October 26
Trading in BDRX resumed on Nasdaq at 9:00 a.m. ET on October 26, 2026, with quotations from 8:55 a.m., after the halt that began at 7:50 p.m. ET on October 23. Nasdaq’s halt list now shows the halt with code T3. As of October 26, 2026, Biodexa had not published a related press release on its website or a new SEC filing; its last filings were dated October 14. On October 8, 2026 the company announced a change in its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400 ordinary shares, expected to take effect on or about October 26, 2026: holders receive one new ADS for every eight old ADS s, with no fractional ADS s; for ADS holders the change has the same effect as a one-for-eight reverse ADS split, and the ordinary shares are not affected. Nasdaq trading halts · Form 6-K, October 8, 2026
Oct 23, 2026
Nasdaq halts trading with code T1 (news pending)
Nasdaq halted trading in BDRX at 7:50 p.m. ET on October 23, 2026 with halt code T1, which indicates a halt pending the release of news. As of October 24, no related announcement had been published and no resumption time had been indicated; trading resumed at 9:00 a.m. ET on October 26 (see the October 26 update). Nasdaq trading halts
Oct 13, 2026
Serenta reaches 100 patients enrolled
Biodexa announced that 100 patients are enrolled in the registrational Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (NCT06950385), which is recruiting at 29 sites in the US and five European countries, with two more sites in Canada expected shortly; the plan is 168 subjects. The protocol provides for a futility analysis after 25 progression-free-survival events and database lock after 75. At the current event rate, management says the futility analysis could take place early in 2027 and database lock around the end of 2027, sooner than originally anticipated; these are company estimates, not fixed dates. Source
Sep 30, 2026
resale registration effective
The registration covering Series P underlying shares became effective. Resale proceeds belong to the selling holder; Biodexa receives additional proceeds only if warrants are exercised for cash under their terms. Source Source
Sep 15, 2026
warrant financing completed
The September 24 prospectus confirms exercise of 2,204,218 existing warrants at US$1.05 and approximately US$2.3 million gross proceeds. New Series P warrants cover 4,408,436 ADS s. Source
Sep 11, 2026
financial and clinical update
June cash was £3.230 million and first-half operating cash use £4.611 million. The bladder study was fully enrolled at 166 patients, with results expected in Q4 2026; financing remained a near-term requirement. Source
BDRX stock catalysts: development and reporting dates
- Q4 2026 — Bladder-cancer study results. Company target
- Early 2027 — Serenta futility analysis at 25 progression-free-survival events. Company event-rate estimate
- Around end 2027 — Serenta database lock after 75 events. Company estimate
Serenta and the bladder-cancer readout
On August 19, 2026, Biodexa reported 87 participants enrolled in Serenta out of 168 planned. The September 11 update raises that count to 92. These are recruitment figures, not numbers of patients with positive outcomes. They show operational progress toward the intended population while leaving the treatment comparison unresolved. Source Source
BDRX cash, warrants and ADS-unit changes
The first-half 2026 net loss was £1.842 million, compared with £3.806 million a year earlier, but operating cash use rose to £4.611 million from £3.304 million. An important reason the smaller accounting loss does not imply a comparable financial improvement is the £2.383 million gain on an equity-settled derivative liability. The company attributes that gain to the fall in its share price. It is not cash generated by selling products or improving the operating business. Source
Merlintrader Health Score · $BDRX
1.70out of 5
Assessed October 2, 2026. Weighted calculation: 1.0×30% + 3.0×30% + 1.0×20% + 1.0×10% + 2.0×10% = 1.70. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Historical financials are in sterling while ADS prices and named financing proceeds are in USD. The October ADS-ratio change makes pre-change price/share-unit comparisons unsafe without adjustment. Financing and dilution remain material.
- The adverse scenario would develop if the bladder-cancer result is disappointing, Serenta encounters execution problems, or capital cannot be raised before resources become inadequate. The June 2026 accounts explicitly identify a material uncertainty relating to going concern. The September financing reduces immediate pressure, but does not establish that all future development is covered. Source Source
BDRX Stock FAQ: Biodexa Pharmaceuticals Questions Answered
Did Biodexa complete the September financing?
Yes. The September 24, 2026 prospectus confirms completion of the September 15 transaction, with approximately US$2.3 million gross proceeds and issuance of new Series P warrants. Gross proceeds are before transaction expenses. Source
How many ordinary shares does one ADS represent?
The September 24, 2026 prospectus states 50 ordinary shares per ADS after the July 30 ordinary-share reorganization and simultaneous ratio change. On October 8, 2026 the company announced a new ratio of 400 ordinary shares per ADS, expected to take effect on or about October 26, 2026, with one new ADS for every eight old ADS s; the ordinary shares are not affected. Applying the ordinary consolidation again to the ADS count would count the same adjustment twice. Form 6-K, October 8, 2026 Source
Is the pro forma cash figure a current bank balance?
No. The £6.804 million in the September prospectus is June 30, 2026 cash adjusted for the specified July and September transactions, not a September or October balance after intervening operating spending. Reported June cash was £3.230 million. Source Source
When are the next bladder-cancer results expected?
The September 11, 2026 update targets the fourth quarter of 2026 for results from the fully enrolled 166-patient study. It is a company window for clinical data, not a fixed announcement day or approval date. Source
Does the FAP grant pay all company expenses?
No. The June 2026 accounts describe matching obligations for the US$20 million CPRIT program and a specific escrow arrangement. Support for eligible study costs is not unrestricted funding of every corporate activity. Source
Primary sources
- October 26, 2026 · Trading resumes after Friday halt; ADS ratio change announced October 8 due on or about October 26
- October 13, 2026 · Serenta reaches 100 patients enrolled
- September 30, 2026 · resale registration effective
- September 15, 2026 · warrant financing completed
- September 11, 2026 · financial and clinical update
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $BDRX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
